| FACET BIOTECH CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20110165154 | COMPOSITIONS AND METHODS USING ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA - Compositions and methods for treating MM are provided herein. | 07-07-2011 |
| 20110117110 | ANTI-EGFR ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR. | 05-19-2011 |
| 20110117013 | COMPOSITIONS AGAINST CANCER ANTIGEN LIV-1 AND USES THEREOF - Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. | 05-19-2011 |
| 20110104153 | USE OF IMMUNOREGULATORY NK CELL POPULATIONS FOR PREDICTING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS - The use of CD56bright NK cell counts and IL-2 receptor protein expression as predictive biomarkers for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis. | 05-05-2011 |
| 20110053209 | USE OF AN IMMUNOREGULATORY NK CELL POPULATION FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS - The use of CD56bright NK cell counts as a biomarker for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis. | 03-03-2011 |
| 20110038864 | Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof - Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. | 02-17-2011 |
| 20110008883 | MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof. | 01-13-2011 |
| 20100273204 | METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS - The use of HLA-DR | 10-28-2010 |
| 20100168397 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 07-01-2010 |
| 20100074841 | Compositions Against Cancer Antigen LIV-1 and Uses Thereof - Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. | 03-25-2010 |
| 20100055098 | METHOD FOR TREATING MULTIPLE SCLEROSIS PATIENTS WITH ANTI-IL2R ANTIBODIES - Methods are disclosed for using anti-IL-2R antibodies for the treatment of MS patients. In certain embodiments, the patients have neutralizing antibodies to IFN-beta. | 03-04-2010 |
| 20100055097 | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION OF IGG ANTIBODIES - This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody. | 03-04-2010 |
| 20090246852 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 10-01-2009 |
| 20090238835 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 09-24-2009 |
| 20090238827 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 09-24-2009 |
